Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial Differences in Adverse Pregnancy Outcomes and Incident Hypertension: A Mediation Analysis.

Journal of the American Heart Association·2026
Same author

Large-scale proteomics in early pregnancy and timing of onset of hypertensive disorders of pregnancy.

medRxiv : the preprint server for health sciences·2026
Same author

Endothelial Susceptibility-Related Genetic Variants and Hypertensive Disorders of Pregnancy-Brief Report.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Harmonizing Maternal and Infant Biospecimen Collection and Processing for Research.

Biopreservation and biobanking·2026
Same author

Fetal brain volumes and brain gyrification index associated with opioid exposure.

Brain communications·2026
Same author

Association between a Periconception Healthy Plant-Based Diet and Adverse Pregnancy Outcomes.

The Journal of nutrition·2026

Related Experiment Videos

Tocolytic therapy: a meta-analysis and decision analysis.

David M Haas1, Thomas F Imperiale, Page R Kirkpatrick

  • 1From the Departments of Obstetrics & Gynecology and Internal Medicine, Division of Gastroenterology, Indiana University School of Medicine; Regenstrief Institute, Inc.; and Medical Decision Modeling, Inc., Indianapolis, Indiana.

Obstetrics and Gynecology
|March 21, 2009
PubMed
Summary
This summary is machine-generated.

Prostaglandin inhibitors are the optimal first-line tocolytic agents for delaying premature labor before 32 weeks gestation. This finding is based on a meta-analysis of randomized controlled trials comparing tocolytic therapies.

Related Experiment Videos

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Neonatal Medicine

Background:

  • Premature labor is a significant concern in obstetrics, necessitating effective tocolytic agents.
  • Current tocolytic therapies vary in efficacy and adverse effects, prompting research into optimal first-line treatments.

Purpose of the Study:

  • To determine the optimal first-line tocolytic agent for the treatment of premature labor.
  • To compare the efficacy and safety of various tocolytic agents in delaying delivery.

Main Methods:

  • A quantitative analysis of 58 randomized controlled trials (RCTs) on tocolysis was performed.
  • Random-effects meta-analysis and decision modeling were used to evaluate maternal and neonatal outcomes.
  • Key outcomes included delay of delivery, adverse effects, respiratory distress syndrome, and neonatal survival.

Main Results:

  • All tocolytic agents significantly delayed delivery compared to placebo at 48 hours and 7 days.
  • Prostaglandin inhibitors demonstrated the best balance of efficacy in delaying delivery and patient tolerance.
  • In a simulated cohort, prostaglandin inhibitors reduced early delivery rates more effectively than other agents.

Conclusions:

  • While all tocolytic agents improve delivery delay, prostaglandin inhibitors are superior to other options.
  • Prostaglandin inhibitors are recommended as the optimal first-line agent for delaying premature labor before 32 weeks gestation.